insights_auto
Pse është rritur EVT 2,05%?
Zhytu më thellëchevron_right
EVT:FRA
Evotec SE
2,89 €
arrow_upward
+2,05%(+0,058) 1D
8 tet, 8:01:17 p.d., GMT+2 · EUR
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për EVT...
Hap
2,89 €
I lartë
2,89 €
I ulët
2,89 €
Kapitalizimi i tregut
478,14Â mln
Vëllimi mesatar
4,65 mijë
Vëllimi
0,00
Maksimumi 52-javor
7,49 €
Minimumi 52-javor
2,73 €
Fitimet për aksion
-1,11 €
Aksionet në qarkullim
148,72Â mln
Numri i punonjësve
4 mijë
Hap
2,89 €
I lartë
2,89 €
I ulët
2,89 €
Kapitalizimi i tregut
478,14Â mln
Vëllimi mesatar
4,65 mijë
Vëllimi
0,00
Maksimumi 52-javor
7,49 €
Minimumi 52-javor
2,73 €
Fitimet për aksion
-1,11 €
Aksionet në qarkullim
148,72Â mln
Numri i punonjësve
4 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
AD HOC NEWS
·
2 orë më parë
Evotec stock loses 3.44 percent after-hours to EUR 2.81
AD HOC NEWS
·
7 orë më parë
Berenberg keeps Hold for Evotec stock at EUR 3.60 target
AD HOC NEWS
·
1 ditë më parë
Evotec loses research chief. Evotec stock falls 2.03 percent
AD HOC NEWS
·
1 ditë më parë
Evotec stock falls 2.1 percent as Q2 revenue drops 16.21 percent
Profili
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
Rreth Evotec SE
Drejtori ekzekutiv-
Punonjësit4,46 mijë
Themeluar më1993
Selia-
SektoriHealth care
Uebsajtievotec.com